Cargando…

Adverse drug reaction reporting and development of pharmacovigilance systems in Bosnia and Herzegovina, Croatia, Serbia, and Montenegro: a retrospective pharmacoepidemiological study

AIM: To compare individual case safety reports (ICSR) rates and characteristics between Croatia, Serbia, Montenegro, and Bosnia and Herzegovina (B&H). METHODS: This retrospective pharmacoepidemiological study used the data from ICSR received by the Agency for Medicines and Medical Devices in B&a...

Descripción completa

Detalles Bibliográficos
Autores principales: Glamočlija, Una, Tubić, Biljana, Kondža, Martin, Zolak, Aleksandar, Grubiša, Nataša
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Croatian Medical Schools 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6045893/
https://www.ncbi.nlm.nih.gov/pubmed/29972735
http://dx.doi.org/10.3325/cmj.2018.59.124
_version_ 1783339747314237440
author Glamočlija, Una
Tubić, Biljana
Kondža, Martin
Zolak, Aleksandar
Grubiša, Nataša
author_facet Glamočlija, Una
Tubić, Biljana
Kondža, Martin
Zolak, Aleksandar
Grubiša, Nataša
author_sort Glamočlija, Una
collection PubMed
description AIM: To compare individual case safety reports (ICSR) rates and characteristics between Croatia, Serbia, Montenegro, and Bosnia and Herzegovina (B&H). METHODS: This retrospective pharmacoepidemiological study used the data from ICSR received by the Agency for Medicines and Medical Devices in B&H in 2011-2016. The number, characteristics, and sources of reports, suspected drugs, and patient characteristics were analyzed. The results were compared with the publicly available data from Croatia, Serbia, and Montenegro. RESULTS: The number of reported adverse drug reactions per one million of inhabitants was lowest in B&H and highest in Croatia. There were significant differences in reporter characteristics, sources of reports, and the percentage of missing data in ICSR, while the Anatomical Therapeutic Chemical product classes, patient’s sex, and adverse drug reaction System Organ Classes were similar. CONCLUSION: Despite the historical and geographical vicinity of B&H and its neighboring countries, there were significant differences in indicators of pharmacovigilance development.
format Online
Article
Text
id pubmed-6045893
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Croatian Medical Schools
record_format MEDLINE/PubMed
spelling pubmed-60458932018-07-18 Adverse drug reaction reporting and development of pharmacovigilance systems in Bosnia and Herzegovina, Croatia, Serbia, and Montenegro: a retrospective pharmacoepidemiological study Glamočlija, Una Tubić, Biljana Kondža, Martin Zolak, Aleksandar Grubiša, Nataša Croat Med J Pharmacoepidemiology AIM: To compare individual case safety reports (ICSR) rates and characteristics between Croatia, Serbia, Montenegro, and Bosnia and Herzegovina (B&H). METHODS: This retrospective pharmacoepidemiological study used the data from ICSR received by the Agency for Medicines and Medical Devices in B&H in 2011-2016. The number, characteristics, and sources of reports, suspected drugs, and patient characteristics were analyzed. The results were compared with the publicly available data from Croatia, Serbia, and Montenegro. RESULTS: The number of reported adverse drug reactions per one million of inhabitants was lowest in B&H and highest in Croatia. There were significant differences in reporter characteristics, sources of reports, and the percentage of missing data in ICSR, while the Anatomical Therapeutic Chemical product classes, patient’s sex, and adverse drug reaction System Organ Classes were similar. CONCLUSION: Despite the historical and geographical vicinity of B&H and its neighboring countries, there were significant differences in indicators of pharmacovigilance development. Croatian Medical Schools 2018-06 /pmc/articles/PMC6045893/ /pubmed/29972735 http://dx.doi.org/10.3325/cmj.2018.59.124 Text en Copyright © 2018 by the Croatian Medical Journal. All rights reserved. http://creativecommons.org/licenses/by/2.5/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Pharmacoepidemiology
Glamočlija, Una
Tubić, Biljana
Kondža, Martin
Zolak, Aleksandar
Grubiša, Nataša
Adverse drug reaction reporting and development of pharmacovigilance systems in Bosnia and Herzegovina, Croatia, Serbia, and Montenegro: a retrospective pharmacoepidemiological study
title Adverse drug reaction reporting and development of pharmacovigilance systems in Bosnia and Herzegovina, Croatia, Serbia, and Montenegro: a retrospective pharmacoepidemiological study
title_full Adverse drug reaction reporting and development of pharmacovigilance systems in Bosnia and Herzegovina, Croatia, Serbia, and Montenegro: a retrospective pharmacoepidemiological study
title_fullStr Adverse drug reaction reporting and development of pharmacovigilance systems in Bosnia and Herzegovina, Croatia, Serbia, and Montenegro: a retrospective pharmacoepidemiological study
title_full_unstemmed Adverse drug reaction reporting and development of pharmacovigilance systems in Bosnia and Herzegovina, Croatia, Serbia, and Montenegro: a retrospective pharmacoepidemiological study
title_short Adverse drug reaction reporting and development of pharmacovigilance systems in Bosnia and Herzegovina, Croatia, Serbia, and Montenegro: a retrospective pharmacoepidemiological study
title_sort adverse drug reaction reporting and development of pharmacovigilance systems in bosnia and herzegovina, croatia, serbia, and montenegro: a retrospective pharmacoepidemiological study
topic Pharmacoepidemiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6045893/
https://www.ncbi.nlm.nih.gov/pubmed/29972735
http://dx.doi.org/10.3325/cmj.2018.59.124
work_keys_str_mv AT glamoclijauna adversedrugreactionreportinganddevelopmentofpharmacovigilancesystemsinbosniaandherzegovinacroatiaserbiaandmontenegroaretrospectivepharmacoepidemiologicalstudy
AT tubicbiljana adversedrugreactionreportinganddevelopmentofpharmacovigilancesystemsinbosniaandherzegovinacroatiaserbiaandmontenegroaretrospectivepharmacoepidemiologicalstudy
AT kondzamartin adversedrugreactionreportinganddevelopmentofpharmacovigilancesystemsinbosniaandherzegovinacroatiaserbiaandmontenegroaretrospectivepharmacoepidemiologicalstudy
AT zolakaleksandar adversedrugreactionreportinganddevelopmentofpharmacovigilancesystemsinbosniaandherzegovinacroatiaserbiaandmontenegroaretrospectivepharmacoepidemiologicalstudy
AT grubisanatasa adversedrugreactionreportinganddevelopmentofpharmacovigilancesystemsinbosniaandherzegovinacroatiaserbiaandmontenegroaretrospectivepharmacoepidemiologicalstudy